These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 32241197

  • 21. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.
    Gitto S, Guarneri V, Sartini A, Andreone P.
    Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798
    [Abstract] [Full Text] [Related]

  • 22. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ, Fuchs M, Freilich B, Schiff E, Kohli A, Lawitz EJ, Hellstern PA, Owens-Grillo J, Van Biene C, Shringarpure R, MacConell L, Shapiro D, Cohen DE.
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [Abstract] [Full Text] [Related]

  • 23. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 24. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N, Janssen AWF, Milona A, Ramos Pittol JM, Hollman DAA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SWC, Kersten S.
    J Hepatol; 2016 May 14; 64(5):1158-1166. PubMed ID: 26812075
    [Abstract] [Full Text] [Related]

  • 25. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists.
    Shah RA, Alkhouri N, Kowdley KV.
    Expert Opin Emerg Drugs; 2020 Sep 14; 25(3):251-260. PubMed ID: 32686578
    [Abstract] [Full Text] [Related]

  • 26. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
    Wang K, Zhang Y, Wang G, Hao H, Wang H.
    Med Res Rev; 2024 Mar 14; 44(2):568-586. PubMed ID: 37899676
    [Abstract] [Full Text] [Related]

  • 27. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
    Musso G.
    Hepatology; 2015 Jun 14; 61(6):2104-6. PubMed ID: 25753820
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao J, Li B, Zhang K, Zhu Z.
    Medicine (Baltimore); 2024 Feb 16; 103(7):e37271. PubMed ID: 38363900
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E, Fiorucci S.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct 16; 1864(10):1422-1437. PubMed ID: 31325638
    [Abstract] [Full Text] [Related]

  • 36. [Treatment Options in Non-alcoholic Fatty Liver Disease].
    Kim W.
    Korean J Gastroenterol; 2017 Jun 25; 69(6):353-358. PubMed ID: 28637104
    [Abstract] [Full Text] [Related]

  • 37. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E.
    Expert Opin Investig Drugs; 2020 Jun 25; 29(6):623-632. PubMed ID: 32552182
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
    Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D.
    Biochem Pharmacol; 2019 Aug 25; 166():212-221. PubMed ID: 31129048
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.